Screener
Niagen Bioscience NAGE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Niagen Bioscience in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Niagen Bioscience’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001386570-26-000030
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Provision for income taxes | 417 | 168 |
| Net income | $6,318 | $5,063 |
| Net income per share attributable to common stockholders: | ||
| Basic | $0.08 | $0.07 |
| Diluted | $0.07 | $0.06 |
| Weighted average common shares outstanding: | ||
| Basic | 79,917 | 77,810 |
| Diluted | 84,566 | 83,232 |
Item 1. FINANCIAL STATEMENTS (unaudited)
FAQ
- What is Niagen Bioscience's EPS (diluted)?
- Niagen Bioscience (NAGE) reported EPS (diluted) of $0.07 in Q1 2026.
- How has Niagen Bioscience's EPS (diluted) changed year-over-year?
- Niagen Bioscience's EPS (diluted) increased by 16.7% year-over-year, from $0.06 to $0.07.
- What is the long-term trend for Niagen Bioscience's EPS (diluted)?
- Over 3 years (2021 to 2025), Niagen Bioscience's EPS (diluted) has grown at a -20.6% compound annual growth rate (CAGR), from -$0.40 to $0.20.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Niagen Bioscience's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude